59 results
8-K/A
EX-99.1
FOLD
Amicus Therapeutics Inc
9 May 22
Amicus Therapeutics Announces First Quarter 2022 Financial Results
12:54pm
launch of AT-GAA.
2022 Environmental, Social, and Governance (ESG) Report published. The Amicus ESG report highlights its dedication to patients … alongside the Company’s environmental, social, and governance responsibilities.
First Quarter 2022 Financial Results
Total revenue in the first quarter
8-K
EX-99.1
FOLD
Amicus Therapeutics Inc
9 May 22
Amicus Therapeutics Announces First Quarter 2022 Financial Results
7:00am
launch of AT-GAA.
2022 Environmental, Social, and Governance (ESG) Report published. The Amicus ESG report highlights its dedication to patients … alongside the Company’s environmental, social, and governance responsibilities.
First Quarter 2022 Financial Results
Total revenue in the first quarter
8-K
EX-10.1
FOLD
Amicus Therapeutics Inc
26 Feb 10
Amicus Therapeutics Announces $18.5 Million Registered Direct Offering of Common Stock
12:00am
taxes, if any.
(2) Please issue the certificate for shares of the Common Stock in the name of:
Print or type name
Social Security or other Identifying … of and delivered to:
Please insert social security or other identifying number:
(Please print name and address)
Dated:
(Date)
(Signature)
(Print name
8-K
EX-10.2
FOLD
Amicus Therapeutics Inc
21 Nov 13
Callidus Biopharma Acquisition Adds Next-Generation Pompe ERT and Enzyme Technology Platform
12:00am
.
(2) Please issue the certificate for shares of the Common Stock in the name of:
Print or type name
Social Security or other Identifying Number … social security or other identifying number:
(Please print name and address)
Dated:
(Date)
(Signature)
(Print name)
Exhibit B
FORM OF ASSIGNMENT
8-K
EX-99.1
1yx3jap1 vpk
23 Mar 20
Other Events
7:01am
8-K
EX-4.1
p8tm619qy7ck56cetsi
26 Feb 10
Amicus Therapeutics Announces $18.5 Million Registered Direct Offering of Common Stock
12:00am
S-1
EX-10.3
y3uej71b33nlore4owxk
17 May 06
IPO registration
12:00am
8-K
EX-10.2
nscqm2 bzbcnfw58
18 Apr 11
Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
12:00am
8-K
EX-99.2
q1dw0la5ecuc8k vd25w
28 Feb 24
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
7:02am
8-K
EX-99.2
d8tnmgzejrbnssiz
9 May 24
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
7:00am
8-K
EX-99.2
3w6xo9cznyvgaotlclj4
8 Nov 23
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-99.2
uodnl3kvo
28 Feb 19
Amicus Therapeutics Announces Full-Year 2018 Financial Results and 2019 Corporate Updates
7:04am
8-K
EX-99.2
9ekun3 f35
8 Aug 23
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-99.2
xrq7 6zrw
10 May 23
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
7:01am
8-K
EX-99.1
mioadk eyuts1f0
16 Nov 22
Corporate OverviewNovember 2022At the Forefront of Therapies for Rare Diseases
7:01am
8-K
EX-99.2
hur5mwzen142om tpm
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
8-K
EX-99.1
cnyhp8rpocqm
14 Sep 22
Corporate Overview September 2022 At the Forefront of Therapies for Rare Diseases
7:00am